MedPath

Carbaglu

These highlights do not include all the information needed to use CARBAGLU safely and effectively. See full prescribing information for CARBAGLU. Carbaglu (carglumic acid) tablets for oral suspensionInitial U.S. Approval: 2010

Approved
Approval ID

10175e73-5172-4dde-a508-8a88b7afc0a1

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 25, 2024

Manufacturers
FDA

Recordati Rare Diseases

DUNS: 767598352

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Carglumic Acid

PRODUCT DETAILS

NDC Product Code52276-312
Application NumberNDA022562
Marketing CategoryC73594
Route of AdministrationORAL
Effective DateJanuary 25, 2024
Generic NameCarglumic Acid

INGREDIENTS (7)

MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
SODIUM LAURYL SULFATEInactive
Code: 368GB5141J
Classification: IACT
HYPROMELLOSE, UNSPECIFIEDInactive
Code: 3NXW29V3WO
Classification: IACT
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
SODIUM STEARYL FUMARATEInactive
Code: 7CV7WJK4UI
Classification: IACT
CARGLUMIC ACIDActive
Quantity: 200 mg in 1 1
Code: 5L0HB4V1EW
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Carbaglu - FDA Drug Approval Details